FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation

Mitochondria—Judges and Executioners of Cell Death Sentences

(2016) Patrick D. Bhola et al.   MOLECULAR CELL

The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics

(2015) A. N. Hata et al.   Cancer Discovery

Cyclin E/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics

(2015) Gaurav S. Choudhary et al.   Oncotarget

TAp73 promotes cell survival upon genotoxic stress by inhibiting p53 activity

(2015) Dongshi Chen et al.   Oncotarget

Tumor Suppression by the Fbw7 Ubiquitin Ligase: Mechanisms and Opportunities

(2014) Ryan J. Davis et al.   CANCER CELL

Regorafenib Inhibits Colorectal Tumor Growth through PUMA-Mediated Apoptosis

(2014) D. Chen et al.   CLINICAL CANCER RESEARCH

An update on the safety and efficacy of regorafenib in the treatment of solid cancers

(2014) Stephen L Chan et al.   Expert Opinion on Drug Metabolism & Toxicology

Regulated protein turnover: snapshots of the proteasome in action

(2014) Sucharita Bhattacharyya et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Dual Regulation of Fbw7 Function and Oncogenic Transformation by Usp28

(2014) Christina Schülein-Völk et al.   Cell Reports

Mcl-1 Ubiquitination: Unique Regulation of an Essential Survival Protein

(2014) Barbara Mojsa et al.   Cells

Targeting Bax interaction sites reveals that only homo-oligomerization sites are essential for its activation

(2013) R Peng et al.   CELL DEATH AND DIFFERENTIATION

Evaluation and critical assessment of putative MCL-1 inhibitors

(2013) S Varadarajan et al.   CELL DEATH AND DIFFERENTIATION

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) George D Demetri et al.   LANCET

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) Axel Grothey et al.   LANCET

Negative Regulation of the Stability and Tumor Suppressor Function of Fbw7 by the Pin1 Prolyl Isomerase

(2012) Sang-Hyun Min et al.   MOLECULAR CELL

Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growth

(2012) C Dudgeon et al.   ONCOGENE

Mcl-1 and FBW7 Control a Dominant Survival Pathway Underlying HDAC and Bcl-2 Inhibitor Synergy in Squamous Cell Carcinoma

(2012) Lei He et al.   Cancer Discovery

MiRNA-27a controls FBW7/hCDC4-dependent cyclin E degradation and cell cycle progression

(2011) Mikael Lerner et al.   CELL CYCLE

An Update on the Current and Emerging Targeted Agents in Metastatic Colorectal Cancer

(2011) Edward Chu   Clinical Colorectal Cancer

SCFFBW7 regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction

(2011) Hiroyuki Inuzuka et al.   NATURE

Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7

(2011) Ingrid E. Wertz et al.   NATURE

The tumour suppressor C/EBPδ inhibits FBXW7 expression and promotes mammary tumour metastasis

(2010) Kuppusamy Balamurugan et al.   EMBO JOURNAL

Mcl-1; the molecular regulation of protein function

(2010) Luke W. Thomas et al.   FEBS LETTERS

Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

(2010) Scott M. Wilhelm et al.   INTERNATIONAL JOURNAL OF CANCER

Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer

(2010) Alberto Bardelli et al.   JOURNAL OF CLINICAL ONCOLOGY

Colorectal cancer

(2010) David Cunningham et al.   LANCET

Chemoprevention by nonsteroidal anti-inflammatory drugs eliminates oncogenic intestinal stem cells via SMAC-dependent apoptosis

(2010) W. Qiu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

RING Domain E3 Ubiquitin Ligases

(2009) Raymond J. Deshaies et al.   Annual Review of Biochemistry

American Society of Clinical Oncology Provisional Clinical Opinion: Testing forKRASGene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy

(2009) Carmen J. Allegra et al.   JOURNAL OF CLINICAL ONCOLOGY

Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival

(2009) Martin Schwickart et al.   NATURE

Molecular Basis of Colorectal Cancer

(2009) Sanford D. Markowitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE